{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:59:23Z","timestamp":1790276363344,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.intimp.2026.117345","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:12:01Z","timestamp":1788772321000},"page":"117345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["QP6126, an orally bioavailable QPCTL inhibitor, with anti-tumor activity in melanoma tumor model"],"prefix":"10.1016","volume":"189","author":[{"given":"Longyan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zening","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoliang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117345_bb0005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","article-title":"Cutaneous melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.117345_bb0010","article-title":"Signal pathways of melanoma and targeted therapy","volume":"6","author":"Guo","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.117345_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102499","article-title":"Mechanisms of resistance to immune checkpoint inhibitors in melanoma: what we have to overcome?","volume":"113","author":"Ziogas","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2026.117345_bb0020","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.117345_bb0025","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1002\/ctm2.943","article-title":"CD47-SIRPalpha blocking-based immunotherapy: current and prospective therapeutic strategies","volume":"12","author":"Bouwstra","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117345_bb0030","doi-asserted-by":"crossref","first-page":"13117","DOI":"10.1073\/pnas.0504184102","article-title":"Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation","volume":"102","author":"Huang","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2026.117345_bb0035","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1021\/acs.jmedchem.1c00325","article-title":"Glutaminyl cyclase, diseases, and development of glutaminyl cyclase inhibitors","volume":"64","author":"Xu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2026.117345_bb0040","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41422-019-0177-0","article-title":"Identification of glutaminyl cyclase isoenzyme isoQC as a regulator of SIRP\u03b1-CD47 axis","volume":"29","author":"Wu","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2026.117345_bb0045","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41591-019-0356-z","article-title":"Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRP\u03b1 axis and a target for cancer immunotherapy","volume":"25","author":"Logtenberg","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117345_bb0050","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41551-019-0454-8","article-title":"High-throughput genome-wide phenotypic screening via immunomagnetic cell sorting","volume":"3","author":"Mair","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.intimp.2026.117345_bb0055","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41590-022-01153-x","article-title":"Loss of the intracellular enzyme QPCTL limits chemokine function and reshapes myeloid infiltration to augment tumor immunity","volume":"23","author":"Barreira da Silva","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2026.117345_bb0060","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2049486","article-title":"QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment","volume":"11","author":"Bresser","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2026.117345_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103644","article-title":"Therapeutic potential of glutaminyl cyclases: current status and emerging trends","volume":"28","author":"Coimbra","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.intimp.2026.117345_bb0070","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/emmm.201100158","article-title":"The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions","volume":"3","author":"Cynis","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.intimp.2026.117345_bb0075","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1021\/acs.jmedchem.4c02247","article-title":"Targeting QPCTL: An emerging therapeutic opportunity","volume":"68","author":"Yu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2026.117345_bb0080","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.trci.2015.08.002","article-title":"A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects","volume":"1","author":"Lues","year":"2015","journal-title":"Alzheimer's Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.intimp.2026.117345_bb0085","author":"V. T. N.V"},{"key":"10.1016\/j.intimp.2026.117345_bb0090","series-title":"Phenylpiperidine Derivatives as Inhibitors of Glutaminyl-Peptide Cyclotransferase and Glutaminyl-Peptide Cyclotransferase like Protein","author":"Willwacher","year":"2024"},{"key":"10.1016\/j.intimp.2026.117345_bb0095","series-title":"3-(6-Pyridin-3-Yl)-2-[4-(4-Methyl-4h-1,2,4-Triazol-3-Yl)Piperidin-1-Yl]Benzonitrile Derivatives and Similar Compounds as QPCTL and QPCT Inhibitors for the Treatment of Cancer","author":"Veal","year":"2024"},{"key":"10.1016\/j.intimp.2026.117345_bb0100","series-title":"Beta-lactam derivatives for the treatment of diseases","author":"Cheng","year":"2022"},{"key":"10.1016\/j.intimp.2026.117345_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101129","article-title":"Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation","volume":"14","author":"Li","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.intimp.2026.117345_bb0110","article-title":"Design, synthesis, and evaluation of 4-(4-methyl-4H-1,2,4-triazol-3-yl)piperidine derivatives as potential glutaminyl cyclase isoenzyme inhibitors for the treatment of cancer","volume":"281","author":"Zhou","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.intimp.2026.117345_bib163","first-page":"454","article-title":"Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy, Signal Transduct","volume":"8","author":"Yu","year":"2023","journal-title":"Target. Ther."},{"key":"10.1016\/j.intimp.2026.117345_bb0115","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41573-023-00703-8","article-title":"Deuterium in drug discovery: progress, opportunities and challenges","volume":"22","author":"Di Martino","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.117345_bb0120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.imlet.2014.02.005","article-title":"Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice","volume":"160","author":"Boross","year":"2014","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.intimp.2026.117345_bb0125","doi-asserted-by":"crossref","first-page":"E2646","DOI":"10.1073\/pnas.1604268113","article-title":"Durable antitumor responses to CD47 blockade require adaptive immune stimulation","volume":"113","author":"Sockolosky","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2026.117345_bb0130","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.117345_bb0135","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.3390\/cells10092320","article-title":"Molecular markers and targets in melanoma","volume":"10","author":"Teixido","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.117345_bb0140","doi-asserted-by":"crossref","first-page":"10184","DOI":"10.1073\/pnas.1710776114","article-title":"Localized CD47 blockade enhances immunotherapy for murine melanoma","volume":"114","author":"Ingram","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2026.117345_bb0145","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fimmu.2020.00018","article-title":"Advances in anti-tumor treatments targeting the CD47\/SIRPalpha axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117345_bb0150","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11030-018-9875-7","article-title":"Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities","volume":"23","author":"Zhong","year":"2019","journal-title":"Mol. Divers."},{"key":"10.1016\/j.intimp.2026.117345_bb0155","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.annonc.2020.04.168","article-title":"P-86 comparison of the pharmacokinetics of donafenib and sorafenib in patients with advanced hepatocellular carcinoma: an open-label, randomized, parallel-controlled, multicentre phase II\/III trial","volume":"31","author":"Qin","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2026.117345_bb0160","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:05:08Z","timestamp":1790273108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926011926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":33,"alternative-id":["S1567576926011926"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117345","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"QP6126, an orally bioavailable QPCTL inhibitor, with anti-tumor activity in melanoma tumor model","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117345"}}